Friday, 30 August 2019

Patent court to review Alexion's Soliris patents on Amgen challenge

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)